Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2015
ASCO 2015 Highlights
Lenalidomide/Dexamethasone versus Bortezomib/Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma: Results of the Phase 3 SWOG S0777 Trial
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Randomized Phase 2 Study of the All-Oral Combination of Ixazomib plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—3-Year Safety and Efficacy Follow-Up
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CHAMPION-1)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Safety of Pomalidomide/Low-Dose Dexamethasone Treatment in Renally Impaired Patients with Relapsed or Refractory Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Pomalidomide/Dexamethasone/Ixazomib versus Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma: Results of Phase 1/2 Alliance A061202
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Novel Kinesin Spindle Protein Inhibitor Filanesib Plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of an Ongoing Phase 1/2b Study (PCYC-1119)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Pembrolizumab plus Lenalidomide/Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (KEYNOTE-023)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Page 178 of 329
175
176
177
178
179
180
181
Top Trending Articles
1.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
2.
From Chaos to Clarity: Data-Driven Denial Prevention
Shawntea (Taya) Gordon, MBA, FACMPE
3.
The Evolving Landscape of Lung Cancer Care
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma